[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Reunion Neuroscience Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100630590","phase-2-re104-safety-and-efficacy-study-in-generalized-anxiety-disorder-100630590",false,"NCT07489651","RE104 Safety and Efficacy Study in Generalized Anxiety Disorder","A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder","Inclusion Criteria:\n\n* Has Generalized Anxiety Disorder as defined by DSM-5-TR\n* If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.\n* Is willing and able to comply with the conditions and requirements of the study\n\nExclusion Criteria:\n\n* Has a significant risk of suicide\n* Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and\u002For borderline personality disorder, or first-degree family history of psychosis or bipolar disorder\n* Has other concurrent psychiatric disorders that is the primary disorder.\n* Has other medically significant conditions rendering unsuitability for the study\n* Has used or will need to use prohibited medications or therapies\n* Has a known sensitivity or intolerance to study intervention or potential rescue medications","ALL","18 Years","74 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.",[27],"Generalized Anxiety Disorder",[29],"GAD","RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":34},"2026-04-20",{"date":38,"type":21},"2027-04",{"name":40,"class":41},"Reunion Neuroscience Inc","INDUSTRY",22,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100593099","phase-2-re104-safety-and-efficacy-study-in-adjustment-disorder-in-cancer-and-other-medical-illnesses-100593099","NCT07002034","RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses","A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses","Inclusion Criteria:\n\n* Has a ≥4 week history of AjD as defined by DSM-5-TR with either depressed mood, or mixed anxiety and depressed mood confirmed by clinical interview with evidence that the AjD was instigated by one of the following medical illnesses (e.g., diagnosis, impact, management, recurrence, prognosis): Cancer, ALS, MS, PD or IPF\n* Is sufficiently ambulatory and capable of self care as necessary to complete study procedures\n* Has normal cognitive function\n* Is on stable use of antidepressants or psychotherapy, or is willing to delay use until the end of study\n* If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant\n* Is willing and able to comply with the conditions and requirements of the study\n\nExclusion Criteria:\n\n* Has a significant risk of suicide\n* Has active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and\u002For borderline personality disorder, or first-degree family history of psychosis or bipolar disorder\n* Has active or a history of central nervous system malignancy\n* Has other medically significant conditions rendering unsuitability for the study\n* Has used or will need to use prohibited medications or therapies\n* Has a known sensitivity or intolerance to study intervention or potential rescue medications","80 Years",{"count":52,"type":21},100,[24],"The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.",[56],"Adjustment Disorder",[58,59,60,61,62,63,64,65],"Cancer","Amyotrophic Lateral Sclerosis (ALS)","Multiple Sclerosis (MS)","Parkinson's Disease (PD)","Idiopathic Pulmonary Fibrosis (IPF)","Depression","Anxiety","Psychiatric Distress","2026-06-01",{"date":68,"type":34},"2026-06-03",{"date":70,"type":34},"2025-07-30",{"date":72,"type":21},"2026-12",{"name":40,"class":41},30,""]